장마감
로그인 회원가입
AQST
AQST
Aquestive Therapeutics Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$3.73
+0.05 ▲ +1.36%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$3.73
+0.00 +0.00%

아쿼스틱 테라퓨틱스(AQST) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$468M
스몰캡
P/E
-
배당수익률
없음
52주 위치
17%
저점 +27% · 고점 -51%
애널리스트
적극 매수
B+
Fundamental health
vs. 성장주 소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 36%
밸류에이션
데이터 부족
재무 안정
Top 18%
Index RUTP/E -EPS (ttm) -0.6Insider Own 5.56%Shs Outstand 124.3MPerf Week -5.45%
Market Cap 0.47BForward P/E -EPS next Y 7.32%Insider Trans -6.42%Shs Float 118.5MPerf Month -16.46%
Enterprise Value 0.49BPEG -EPS next Q -0.1Inst Own 55.14%Short Float 14.07%Perf Quarter -8.58%
Income -0.07BP/S 9.31EPS this Y 47.44%Inst Trans -1.88%Short Ratio 8.84Perf Half Y 15.12%
Sales 0.05BP/B -EPS next 5Y 28.3%ROA -56.63%Short Interest 16.67MPerf YTD -42.26%
Book/sh -0.27P/C 4.23EPS past 3/5Y 11.13% 13.92%ROE -52W High -50.6% ($7.55)Perf Year -10.12%
Cash/sh 0.88P/FCF -Sales past 3/5Y -2.24% -0.58%ROIC -81.84%52W Low 27.3% ($2.93)Perf 3Y 119.41%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -3.31%Gross Margin 63.45%Volatility(W/M) 5.13% 5.19%Perf 5Y 10.36%
Dividend TTM -EV/Sales 9.76Sales Y/Y TTM -7.3%Oper. Margin -111.18%ATR (14) 0.21Perf 10Y -
Dividend Ex-Date -Quick Ratio 3.85EPS Q/Q 72.64%Profit Margin -137.08%RSI (14) 37.1Recom 1
Dividend Gr. 3/5Y -Current Ratio 4.1Sales Q/Q 65.67%SMA20 -8.12% ($4.06)Beta 1.49Target Price $8.75
Payout -Debt/Eq -Earnings 2026/5/13SMA50 -10.54% ($4.17)Rel Volume 0.96Prev Close $3.68
Employees 147LT Debt/Eq -EPS/Sales Surpr. 47.92% 32.58%SMA200 -21.54% ($4.75)Avg Volume(3M) 1.89MPrice $3.73
IPO 2018/7/25Option/Short Yes/YesTrades 6899Volume 1,812,549Change 1.36%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $14M (YoY +66%) · 순이익 $-8M (YoY +65%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Aquestive Therapeutics Inc (AQST) Investment Analysis

What kind of company is Aquestive Therapeutics Inc?

아쿼스틱 테라퓨틱스(AQST) 성장주
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility

💊 Aquestive Therapeutics is a pharmaceutical company that develops and commercializes treatments for central nervous system disorders and allergic reactions based on its proprietary PharmFilm oral-soluble film technology. Founded in 2004 and headquartered in the United States, the company pursues a differentiated approach to needle-free drug delivery, including a film-based drug portfolio for seizures, epilepsy, and addiction, as well as a sublingual epinephrine film for anaphylaxis. Its US Nasdaq-listed ticker is AQST.

Learn more about Aquestive Therapeutics Inc →
Market Cap
$0.5B
Approx. KRW 0.6 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3259
Employees147people
IPO2018/07/25
Current Price$3.73 ≈ 5,110원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 14일 (목) · 장 마감 후
🔔 Earnings release 2026년 5월 13일 (수) · 장 마감 후 EPS +47.9% 매출 +32.6%
🔔 Earnings release 2026년 3월 4일 (수) · 장 마감 후 EPS -100.0% 매출 -2.0%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-111.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-137.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
63.5%
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 57.7% · Top 36%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROA
Annual earnings relative to total company assets
-56.6%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-81.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
4.10
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
3.85
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$8.75
현재가 대비 +134.6%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+7.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+28.3%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
+23.3%
평균 서프라이즈
2026.05.13
상회
실적 $-0.05 · 예상 $-0.13 +64.7%
2026.03.04
하회
실적 $-0.14 · 예상 $-0.12 -18.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+47.4%
우수
My positionTop 25%
Low range Average High range
성장주 소형주 Median 16.2% · Top 9%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+7.3%
부진
My positionBottom 25%
Low range Average High range
성장주 소형주 Median 17.5% · Bottom 22%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+28.3%
우수
My positionTop 5%
Low range Average High range
성장주 소형주 Median 18.9% · Top 3%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+11.1%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 8.7% · Top 47%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+13.9%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 2.9% · Top 32%
Past 5-Year Revenue
How much revenue grew over the past 5 years
-0.6%
부진
My positionBottom 25%
Low range Average High range
성장주 소형주 Median 10.4% · Bottom 17%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+65.7%
우수
My positionTop 5%
Low range Average High range
성장주 소형주 Median 7.0% · Top tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -58%p below the market
AQST +10.4% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-58.0%p
Significantly behind the market
vs Health Care (XLV)
-14.1%p
behind the sector average
1-year basis
vs S&P 500
-26.1%p
behind the market
vs Health Care (XLV)
-29.8%p
behind the sector average
Rank among peers
5-year return Upper-Mid (33%) Based on 25 peers
1-year return Lower-Mid (lower 44%) Based on 28 peers
Current position within 52-week range
Low (-27.3%p) High (-50.6%p)
Current price is 27.3% above the 52-week low and 50.6% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-26.8%
Annualized volatility
52.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $3.73 below the midline ($4.06). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.130 < Signal -0.083 in negative zone + Hist negative (-0.047). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 37.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 16.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
9.31x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Bottom 1% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$8.75 vs. current price +134.6%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 소형주

Who owns it?

Ownership backdrop is unfavorable
Insider modest net selling -6.4% · Institutional net selling -1.9% · Short interest elevated 14.1% · Short interest fell -3.3%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-6.4%
Insiders net selling
🏦 Institutions (funds & investors)
-1.9%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 55.1%
Adequate institutional weight
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 5.6%
Meaningful insider stake
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 39.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
14.1%
Somewhat high
Healthcare 소형주 Median 11.2%
Past 90 days 📉 -3.3%p decrease
Short interest days to cover
8.8 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 124.3M주
Float (tradable shares) 118.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding AQST

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
AQST AQST This Stock
$468.0M- - - - +1.4%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 아쿼스틱 테라퓨틱스(AQST)?

아쿼스틱 테라퓨틱스(AQST) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of AQST?

The market cap of AQST is approximately $468M, ranking 3,259 within its sector.

What is the 52-week high and low for AQST?

AQST has recorded a 52-week high of $7.55 and a low of $2.93.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.